For research use only. Not for therapeutic Use.
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1[1].
Catalog Number | I018063 |
CAS Number | 2299226-01-8 |
Synonyms | 2-[6-(diethylamino)pyridin-3-yl]-1-[(1-ethylpyrazol-3-yl)methyl]-N-methylbenzimidazole-5-carboxamide |
Molecular Formula | C24H29N7O |
Purity | ≥95% |
InChI | InChI=1S/C24H29N7O/c1-5-29(6-2)22-11-9-18(15-26-22)23-27-20-14-17(24(32)25-4)8-10-21(20)31(23)16-19-12-13-30(7-3)28-19/h8-15H,5-7,16H2,1-4H3,(H,25,32) |
InChIKey | LYVJDLHFTGYNAV-UHFFFAOYSA-N |
SMILES | CCN1C=CC(=N1)CN2C3=C(C=C(C=C3)C(=O)NC)N=C2C4=CN=C(C=C4)N(CC)CC |
Reference | [1]. Medina, et al. 5-(1H-Benzo[d]imidazol-2-yl)pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)pyridin-2-amine derivatives as c-MYC and p300/CBP histone acetyltransferase inhibitors for treating cancer and their preparation. |